189 related articles for article (PubMed ID: 31559512)
1. Evaluation of intravenous direct thrombin inhibitor monitoring tests: Correlation with plasma concentrations and clinical outcomes in hospitalized patients.
Beyer JT; Lind SE; Fisher S; Trujillo TC; Wempe MF; Kiser TH
J Thromb Thrombolysis; 2020 Feb; 49(2):259-267. PubMed ID: 31559512
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the aPTT with alternative tests for monitoring direct thrombin inhibitors in patient samples.
Lind SE; Boyle ME; Fisher S; Ishimoto J; Trujillo TC; Kiser TH
Am J Clin Pathol; 2014 May; 141(5):665-74. PubMed ID: 24713737
[TBL] [Abstract][Full Text] [Related]
3. Laboratory Monitoring of Parenteral Direct Thrombin Inhibitors.
Van Cott EM; Roberts AJ; Dager WE
Semin Thromb Hemost; 2017 Apr; 43(3):270-276. PubMed ID: 28052306
[TBL] [Abstract][Full Text] [Related]
4. Monitoring Direct Thrombin Inhibitors With Calibrated Diluted Thrombin Time vs Activated Partial Thromboplastin Time in Pediatric Patients.
Hasan RA; Pak J; Kirk CJ; Friedland-Little JM; Chandler WL
Am J Clin Pathol; 2023 Jan; 159(1):60-68. PubMed ID: 36351044
[TBL] [Abstract][Full Text] [Related]
5. Comparing direct thrombin inhibitors using aPTT, ecarin clotting times, and thrombin inhibitor management testing.
Gosselin RC; King JH; Janatpour KA; Dager WE; Larkin EC; Owings JT
Ann Pharmacother; 2004 Sep; 38(9):1383-8. PubMed ID: 15238620
[TBL] [Abstract][Full Text] [Related]
6. Monitoring of Argatroban and Lepirudin: What is the Input of Laboratory Values in "Real Life"?
Seidel H; Kolde HJ
Clin Appl Thromb Hemost; 2018 Mar; 24(2):287-294. PubMed ID: 28320219
[TBL] [Abstract][Full Text] [Related]
7. Measuring direct thrombin inhibitors with routine and dedicated coagulation assays: which assay is helpful?
Curvers J; van de Kerkhof D; Stroobants AK; van den Dool EJ; Scharnhorst V
Am J Clin Pathol; 2012 Oct; 138(4):551-8. PubMed ID: 23010710
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia.
Dang CH; Durkalski VL; Nappi JM
Pharmacotherapy; 2006 Apr; 26(4):461-8. PubMed ID: 16553503
[TBL] [Abstract][Full Text] [Related]
9. Monitoring of the anticoagulants argatroban and lepirudin: a comparison of laboratory methods.
Ivandic B; Zorn M
Clin Appl Thromb Hemost; 2011 Oct; 17(5):549-55. PubMed ID: 20834029
[TBL] [Abstract][Full Text] [Related]
10. UNBLOCK: an open-label, dose-finding, pharmacokinetic and safety study of bivalirudin in children with deep vein thrombosis.
O'Brien SH; Yee DL; Lira J; Goldenberg NA; Young G
J Thromb Haemost; 2015 Sep; 13(9):1615-22. PubMed ID: 26180006
[TBL] [Abstract][Full Text] [Related]
11. Comparison of bivalirudin and argatroban for the management of heparin-induced thrombocytopenia.
Skrupky LP; Smith JR; Deal EN; Arnold H; Hollands JM; Martinez EJ; Micek ST
Pharmacotherapy; 2010 Dec; 30(12):1229-38. PubMed ID: 21114390
[TBL] [Abstract][Full Text] [Related]
12. Assays to Monitor Bivalirudin.
Davidson S
Methods Mol Biol; 2023; 2663():369-380. PubMed ID: 37204724
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of argatroban and bivalirudine in patients with suspected heparin-induced thrombocytopenia.
Vo QA; Lin JK; Tong LM
Ann Pharmacother; 2015 Feb; 49(2):178-84. PubMed ID: 25515865
[TBL] [Abstract][Full Text] [Related]
14. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation.
Warkentin TE; Greinacher A; Craven S; Dewar L; Sheppard JA; Ofosu FA
Thromb Haemost; 2005 Nov; 94(5):958-64. PubMed ID: 16363236
[TBL] [Abstract][Full Text] [Related]
15. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban.
Finkle CD; St Pierre A; Leblond L; Deschenes I; DiMaio J; Winocour PD
Thromb Haemost; 1998 Feb; 79(2):431-8. PubMed ID: 9493603
[TBL] [Abstract][Full Text] [Related]
16. Comparison of bivalirudin to lepirudin and argatroban in patients with heparin-induced thrombocytopenia.
Bain J; Meyer A
Am J Health Syst Pharm; 2015 Sep; 72(17 Suppl 2):S104-9. PubMed ID: 26272889
[TBL] [Abstract][Full Text] [Related]
17. How to best monitor bivalirudin anticoagulant effect for ECMO and VAD-Comparison of four assay methods.
Teruya J; Bruzdoski K; Hensch L; Hui SR; Kostousov V
Int J Lab Hematol; 2022 Jun; 44(3):589-594. PubMed ID: 34939341
[TBL] [Abstract][Full Text] [Related]
18. Monitoring of argatroban and lepirudin anticoagulation in critically ill patients by conventional laboratory parameters and rotational thromboelastometry - a prospectively controlled randomized double-blind clinical trial.
Beiderlinden M; Werner P; Bahlmann A; Kemper J; Brezina T; Schäfer M; Görlinger K; Seidel H; Kienbaum P; Treschan TA
BMC Anesthesiol; 2018 Feb; 18(1):18. PubMed ID: 29426286
[TBL] [Abstract][Full Text] [Related]
19. Chromogenic and Clot-Based Bivalirudin Assays for Monitoring Anticoagulation.
Raghavendran P; Tillman BF; Wheeler AP; Gailani D
J Appl Lab Med; 2023 Nov; 8(6):1074-1083. PubMed ID: 37811688
[TBL] [Abstract][Full Text] [Related]
20. Bivalirudin Monitoring in Pediatric Ventricular Assist Device and Extracorporeal Membrane Oxygenation: Analysis of Single-Center Retrospective Cohort Data 2018-2022.
Engel ER; Perry T; Block M; Palumbo JS; Lorts A; Luchtman-Jones L
Pediatr Crit Care Med; 2024 Jul; 25(7):e328-e337. PubMed ID: 38713010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
